Aller au contenu principal
2026 article

Hormone levels of female patients with SLE after anti-CD19 CAR T-cell treatment do not indicate a signal of impaired ovarian reserve

0Citations signalées — pas une note de qualité
5Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

OBJECTIVES: Women with SLE are at increased risk of infertility due to disease activity and exposure to gonadotoxic therapies. Anti‑CD19 chimeric antigen receptor (CAR) T‑cell therapy has recently been shown to induce durable, drug‑free remission in refractory SLE; however, its effects on ovarian function remain unknown. We assessed longitudinal changes in reproductive endocrine markers to evaluate the impact of CAR T‑cell therapy on ovarian reserve and hypothalamic-pituitary-ovarian (HPO) axis function. METHODS: Women with severe, treatment‑refractory SLE receiving autologous anti‑CD19 CAR T‑cell therapy (Miltenyi Biomedicine) in conjunction with standard lymphodepletion at two tertiary care centres were studied. Anti‑Müllerian hormone (AMH), oestradiol (E2), progesterone, follicle‑stimulating hormone (FSH), luteinizing hormone (LH) and prolactin were measured at baseline and 12 months after therapy. Blood samples were obtained independent of menstrual cycle phase. Paired statistical analyses were performed. RESULTS: Thirteen women were included; median age at CAR T‑cell therapy was 27 years. AMH levels were stable (1.54 ng/ml [IQR 0.64-3.15] vs 2.14 ng/ml [0.63-3.26]; P = 0.886). E2 (243 pmol/l [186-346] vs 484 pmol/l [277-829]; P = 0.339) and progesterone (0.90 nmol/l [0.80-0.90] vs 1.80 nmol/l [0.90-3.40]; P = 0.054) showed substantial variability without significant longitudinal change. FSH increased modestly (6.60 IU/l [4.00-7.90] vs 7.20 IU/l [4.50-9.90]; P = 0.033) without a concomitant decline in AMH. LH (6.10 IU/l [5.10-12.90] vs 7.00 IU/l [5.00-12.90]; P = 0.946) and prolactin (10.0 µg/l [8.0-10.0] vs 8.0 µg/l [5.0-9.0]; P = 0.123) remained stable. CONCLUSION: Anti‑CD19 CAR T‑cell therapy, including standard lymphodepletion, showed no signal of impaired ovarian reserve, as assessed by AMH and hormone profiles. Observed hormonal changes, including FSH, should be interpreted with caution given study limitations.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Hormone levels of female patients with SLE after anti-CD19 CAR T-cell treatment do not indicate a signal of impaired ovarian reserve
Date Crossref
01/08/2026
Éditeur
Oxford University Press (OUP)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

CAR-T cell therapy researchSystemic Lupus Erythematosus ResearchBiosimilars and Bioanalytical Methods

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.